Released Nov 10, 2025, before the open
10-Q filed Nov 10, 2025, 41 days after period end · 0002023658-25-000109
Q3 2025 · 10-Q
Revenue—
Net Income-$36.33M-$36.33M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.67-$0.67 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$40,676,000N/M
Operating Cash Flowderived-$29,248,000N/M
Free Cash Flowderived-$29,290,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|
| Net Income | -$36.33M | -$17.48M | -$22.85M |
| EPS Diluted | -$0.67 | -$1.60 | -$38.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR